January 7, 2019
F2G combines €24 million loan and investment from Chinese Morningside to speed up its fungal infections treatment candidate olorofim
A UK- and Austria-based Biotech company F2G Ltd, has raised funding from life science investor Morningside Venture Investments Ltd. (Morningside), after borrowing €24 million from the European Investment Bank (EIB) in November 2018 to speed up the phase 2 study for its lead candidate, a treatment for invasive fungal infections, olorofim.